Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Trump falsely linked Tylenol to autism, causing stock drop; shares rebounded after company denied any risk.
Shares in Kenvue, maker of Tylenol, surged over 6% at Tuesday’s market open after a nearly 8% drop the previous day, following former President Donald Trump’s unfounded claims linking Tylenol to autism and urging pregnant women and parents to avoid it.
Trump’s statements, repeated during a White House news conference, echoed discredited theories without new scientific support, sparking public concern despite Kenvue’s strong denial of any credible connection between acetaminophen and autism.
The company emphasized that avoiding the drug during fever could pose greater health risks and noted that most related lawsuits have been dismissed.
Analysts attributed the stock rebound to market confidence that the claims lacked evidence, with limited long-term risk expected.
The controversy highlighted the impact of political figures on public health perceptions, even when assertions are unsupported by science.
Trump falsamente relacionó el Tylenol con el autismo, causando una caída en las acciones; las acciones se recuperaron después de que la compañía negó cualquier riesgo.